Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.
Post-hoc analysis revealed variability in placebo response, highlighting trial design challenges for future studies. On Thursday, Vertex Pharmaceuticals Incorporated VRTX announced results from ...
The post hoc analysis included 438 patients who received T-AC and 2111 who received TC. Compared to patients receiving TC, those who had T-AC were generally younger (mean age, 53 vs 55 years ...